Charles River Laboratories | CRL - Ebitda


Charles River Laboratories reported $229.8M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Agilent USD 456M 84M Dec/2025
Align Technology USD 260.87M 77.03M Dec/2025
Bio-Rad Laboratories USD 983.8M 1.36B Dec/2025
Bruker USD 110M 101.6M Mar/2026
Cardinal Health USD 1.09B 109M Mar/2026
Charles River Laboratories USD 229.8M 28.26M Mar/2026
Cigna USD 2.86B 56M Mar/2025
CVS Health USD 5.83B 2.08B Mar/2026
Danaher USD 1.92B 204M Mar/2026
Dentsply International USD 129M 6M Mar/2026
Elevance Health USD 4.21B 2.02B Mar/2026
Humana USD 2.06B 2.35B Mar/2026
Illumina USD 469M 137M Dec/2025
Incyte USD 367.97M 46.53M Mar/2026
Intrexon USD -24.7M 2.92M Jun/2024
IQVIA Holdings USD 932M 114M Mar/2026
Laboratory Of America USD 605.6M 17.5M Mar/2026
Lakefront Biotherapeutics EUR -63.7M 624.2M Mar/2026
Lonza CHF 1.01B 54M Dec/2025
McKesson USD 1.88B 206M Dec/2025
Merck EUR 1.53B 87M Mar/2026
Mettler Toledo International USD 278.99M 100.24M Mar/2026
Novartis USD 5.3B 530M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Quest Diagnostics USD 557M 20M Mar/2026
Revvity USD 272.91M 24M Mar/2026
Thermo Fisher Scientific USD 2.7B 464M Mar/2026
United Therapeutics USD 379.5M 83.4M Dec/2025
UnitedHealth USD 9.43B 567M Jun/2026
Veradigm USD 38.81M 29.61M Sep/2022
Waters USD 380.97M 85.83M Dec/2025
West Pharmaceutical Services USD 226.2M 7.7M Mar/2026